Literature DB >> 31429619

Sub-Tenon Sustained Controllable Delivery of Dexamethasone for Treating Severe Acute Experimental Uveitis.

Libei Zhao1, Xuetao Huang2, Manqiang Peng1, Qian Tan1, Wenxiang Lin1, Muhammad Ahmad Khan1, Qiongyan Tang1, Ding Lin1.   

Abstract

PURPOSE: To evaluate the efficacy of dexamethasone (DXM) through sub-tenon sustained controllable drug delivery system (SSCDDS) for treating severe acute experimental uveitis.
METHODS: Rabbits were treated with either DXM (treated group) or normal saline (control group) through SSCDDS. Clinical signs of uveitis were assessed at days 1, 3, 5, 7, and 14 after treatment. Histopathologic examinations were performed to evaluate inflammatory cell infiltration on posttreatment days 7 and 14.
RESULTS: All signs of experimental uveitis were reduced by SSCDDS of DXM according to clinical criteria, and the treated group had significantly less inflammation than the control group (p<0.05). Histopathologic examinations showed severe inflammation and marked inflammatory cell infiltration in the control group, but minimal inflammation in the treated group.
CONCLUSIONS: Sub-tenon sustained controllable delivery of DXM effectively suppresses severe acute inflammation in a rabbit model of uveitis. The proposed minimal invasive system might be a promising candidate for managing severe ocular diseases.

Entities:  

Keywords:  Dexamethasone; drug delivery system; sub-tenon; treatment; uveitis

Mesh:

Substances:

Year:  2019        PMID: 31429619     DOI: 10.1080/09273948.2019.1643027

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  1 in total

1.  Efficacy of Sub-Tenon Micro-Perfusion of Cyclophosphamide in Rabbits with Severe Ocular Inflammation.

Authors:  Libei Zhao; Manqiang Peng; Wenxiang Lin; Qian Tan; Muhammad Ahmad Khan; Ding Lin
Journal:  Drug Des Devel Ther       Date:  2020-08-20       Impact factor: 4.162

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.